Hetero Gets Emergency Use Nod For Generic Version Of Covid Drug Tocilizumab

COVID-19: Hetero expects to make the treatment, tocilizumab, available in India by the end of the month under the brand name Tocira.

Hetero Gets Emergency Use Nod For Generic Version Of Covid Drug Tocilizumab

COVID-19 treatment: Tocilizumab has been facing a global shortage. (File)

Bengaluru:

Indian drug developer Hetero said on Monday it has received emergency use approval from the country's health authorities to make a generic version of Roche Holding AG's COVID-19 drug.

Hetero expects to make the treatment, tocilizumab, available in India by the end of the month under the brand name Tocira. Tocilizumab has been facing a global shortage as the highly contagious COVID-19 Delta variant drives up cases in several countries.

COVID-19 cases in India have declined from levels hit during the second wave in April and May, although health experts believe that the country should brace for a third wave by October.

Roche's blockbuster arthritis drug, tocilizumab, cuts the risk of death among patients hospitalised with severe COVID-19 along with shortening the recovery time and reducing the need for mechanical ventilation.

Tocira will be made by Hetero's unit at its Hyderabad facility.

Hetero, which makes COVID-19 treatments like remdesivir and favipiravir, had also sought emergency approval for Merck's COVID-19 drug molnupiravir in July.

(This story has not been edited by NDTV staff and is auto-generated from a syndicated feed.)